Joint Clinical Trials Office

You are here

A Phase2, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects with Advanced Malignancies (RX-3117-P1-01)

Clinical Trial Details

This clinical trial is for men and women diagnosed with an advanced or metastatic cancer. This research study is testing an experimental (investigational) drug called RX-3117 for advanced or metastatic cancers. The purpose of this Phase 2 study is to evaluate if study drug RX-3117 is safe and effective in people with advanced bladder cancer. The study will measure how much study drug is in your blood at specific time points. 

In this study, patients will receive a specific dose of RX-3117 to be taken 5 times per week by mouth for 3 weeks followed by 1 week rest. It is estimated that subjects will participate in the study for approximately 24 months. Patients will continue on treatment as long as they are responding to therapy and not experiencing unacceptable side effects.

Key Eligibility: 
  •  Men and women age 18 and older
  •  Diagnosis of advanced bladder cancer
  •  ECOG Performance Status of 0-1
  •  Detailed eligibility reviewed when you contact the study team

Study contact by location

Upper East Side - Manhattan

Contact(s)

Alice Mercado, RN, MBA, CCRC
(646) 962-3080
alm2051@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1603017112

Status

Open to Enrollment

Age Group

Adult

Sponsor